InDex Pharmaceuticals takes a TLR9 approach to ulcerative colitis
This article was originally published in Scrip
Executive Summary
InDex Pharmaceuticals has begun a Phase III trial of its lead drug product Kappaproct (DIMS0150), which it hopes will reduce the need for colectomy in patients with severe ulcerative colitis.